Zenas BioPharma (NASDAQ:ZBIO) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Zenas BioPharma (NASDAQ:ZBIO) from a strong sell rating to a sell rating in a research report report published on Saturday morning.

Other analysts also recently issued reports about the company. Zacks Research downgraded Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 17th. Guggenheim raised their price target on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research note on Thursday. Morgan Stanley raised their price target on Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Zenas BioPharma currently has a consensus rating of “Hold” and an average price target of $44.29.

Zenas BioPharma Stock Performance

Shares of ZBIO opened at $18.34 on Friday. The business’s fifty day simple moving average is $21.21 and its two-hundred day simple moving average is $26.75. The company has a current ratio of 11.94, a quick ratio of 5.61 and a debt-to-equity ratio of 1.04. Zenas BioPharma has a 12 month low of $8.91 and a 12 month high of $44.60. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -2.17 and a beta of -0.61.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period in the previous year, the company earned ($0.80) EPS. Research analysts anticipate that Zenas BioPharma will post -4.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Hongbo Lu bought 3,768 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The shares were bought at an average cost of $18.63 per share, with a total value of $70,197.84. Following the acquisition, the director owned 426,736 shares in the company, valued at $7,950,091.68. This trade represents a 0.89% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Fairmount Funds Management Llc bought 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 31st. The stock was bought at an average cost of $20.00 per share, for a total transaction of $3,000,000.00. Following the completion of the acquisition, the director owned 2,359,025 shares in the company, valued at $47,180,500. This trade represents a 6.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 213,768 shares of company stock valued at $4,137,398. 22.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently bought and sold shares of ZBIO. Quarry LP raised its holdings in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. bought a new stake in Zenas BioPharma during the third quarter valued at about $30,000. GF Fund Management CO. LTD. bought a new stake in Zenas BioPharma during the fourth quarter valued at about $38,000. BNP Paribas Financial Markets raised its holdings in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after acquiring an additional 1,716 shares during the period. Finally, CWM LLC raised its holdings in Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.